Allurion Q4 revenue up 22-37% QoQ; FY2025 revenue ~$15M

ALLURION TECHNOLOGIES, INC.

2025-FY EPS reported -$3.81 revenue$15,230,000

Q4 2025 revenue $3.3-3.7M (22-37% QoQ increase); full-year revenue ~$15M.
Substantial QoQ and YoY improvement in operating expenses and operating loss.
CEO cites strategic pivot taking hold; potential FDA approval of Allurion Smart Capsule in 2026.

item 2.02 item 9.01

ALLURION TECHNOLOGIES, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-010462

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.